XENE — Xenon Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $3.30bn
- $2.66bn
- 43
- 29
- 63
- 41
Annual income statement for Xenon Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 6.83 | 32.2 | 18.4 | 9.43 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 49.6 | 64.5 | 97.4 | 139 | 214 |
| Operating Profit | -42.8 | -32.3 | -79 | -129 | -214 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -41.6 | -29.1 | -78.9 | -125 | -183 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -41.6 | -28.8 | -78.9 | -125 | -182 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -41.6 | -28.8 | -78.9 | -125 | -182 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -40 | -28 | -77.1 | -125 | -182 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.54 | -0.792 | -1.77 | -2.06 | -2.73 |